Introduction
Angiogenesis, the process by which new blood vessels are formed from a pre-existing vascular network, is essential during embryonic tissue development and is implicated in a number of pathological situations including cancer. Among the dozen of angiogenic factors characterized to date, vascular endothelial growth factor (VEGF) has emerged as the most important regulator of physiological and pathological angiogenesis (Ferrara et al., 2003) . Hypoxia, growth factors and hormones control VEGF expression through both transcriptional and post-transcriptional mechanisms. VEGF mRNA has a constitutively short half-life (60-180 min). It is stabilized under hypoxic conditions through the binding of proteins (HuR, hRNP-L) to AUrich elements (AREs) present in its 3 0 -untranslated region (3 0 -UTR) (Goldberg-Cohen et al., 2002; Shih and Claffey, 1999) . AREs, which have been identified in the 3 0 -UTRs of several short-lived mRNAs as important determinants of RNA instability, are composed of several consensus pentameric AUUUA, nonameric UUAUUUA(A/U)(A/U) or simply U-rich motifs (Chen and Shyu, 1995) .
To date, the mechanisms of VEGF mRNA destabilization remain unknown. In a previous work, we observed that ACTH treatment of primary adrenocortical cells results in a rapid and transient increase in VEGF mRNA levels (peaking at 2-3 h) and a delayed but sustained induction of TIS11b mRNA (reaching a maximum after 3-5 h) (Chinn et al., 2002) . As the increase of TIS11b expression was concomitant with VEGF mRNA decay, we postulated that the product of this gene might negatively control VEGF mRNA expression. This hypothesis was supported by the following pieces of information. TIS11b belongs to a family of RNA-binding proteins (comprising also TIS11/TTP/tristetraprolin and TIS11d) that share characteristic tandem CCCH-type zinc-finger domains. The canonical family member, TTP, has been shown to bind to AREs in the 3 0 -UTR of tumour necrosis factor a (TNFa) mRNA through these zinc-finger domains, and to decrease TNFa mRNA stability by promoting its deadenylation and degradation (Carballo et al., 1998; Lai et al., 2003) . All members of the family are involved in regulation of several short-lived cytokine mRNAs including granulocyte macrophage colony-stimulating factor (GM-CSF), and interleukin 3 (Carballo et al., 2000; Stoecklin et al., 2000) and appear to share similar ARE-binding and mRNA-destabilizing activities. However, their tissue-specific expression and regulation presumably contribute to their specificity of action. Here, we studied the effects of TIS11b and its related family members on VEGF mRNA stability and characterized the molecular interaction between TIS11b and VEGF mRNA 3 0 -UTR. Our original data show that (i) TIS11b binds to a 75 bp-long domain of VEGF mRNA that contains two AU-rich motifs, (ii) TIS11b is complexed with VEGF mRNA in living cells as determined by ribonucleoprotein (RNP) complex immunoprecipitation, (iii) binding of TIS11b to VEGF mRNA results in its destabilization, (iv) TIS11b is a physiological inhibitor of VEGF mRNA stability in adrenocortical cells since siRNA-mediated downregulation of TIS11b results in increased basal and ACTHstimulated VEGF mRNA levels.
Results
Effect of TIS11b and related proteins on VEGF mRNA 3 0 -UTR
We previously observed that expression of TIS11b in 3T3 cells expressing the luciferase reporter gene cloned upstream of the rat VEGF 3 0 -UTR (a construct hereafter named Luc-V3 0 ) dose-dependently decreased luciferase activity (Chinn et al., 2002) . We first investigated the effects of tristetraprolin (TTP) family members on the activity of this same reporter gene. As shown in Figure 1a , all three members (TIS11, TIS11b and TIS11d) induced a comparable dose-dependent inhibitory effect on luciferase activity, reaching 50-60% inhibition when 50 ng of plasmid were transfected. Transfection of a control b-galactosidase expression plasmid induced a slight dose-dependent inhibition of reporter gene activity, which did not exceed 25%. As the effects were similar with all family members, we pursued the study with TIS11b. We investigated whether decreased luciferase activity resulted from decreased mRNA levels. Quantitative real-time RT-PCR was used to measure Luc-V3 0 mRNA levels following transfection of increasing concentrations of either a TIS11b-or a b-galactosidase-expression plasmid. We observed that Luc-V3 0 mRNA levels were dose-dependently reduced in TIS11b-expressing cells similarly to the reporter gene activity (Figure 1b) . We then examined whether this decrease in mRNA levels resulted from changes in the stability of Luc-V3 0 mRNA. The half-life of this mRNA was measured in b-galactosidase-and TIS11b-transfected cells, using the transcription inhibitor DRB. In the presence of TIS11b, the half-life of Luc-V3 0 mRNA was reduced from 130 to 60 min (Figure 1c ). This result prompted us to analyse the physical interaction between TIS11b and a radiolabeled fragment encoding the fulllength 3 0 -UTR of VEGF mRNA by EMSA (Figure 1d ). Escherichi coli-expressed TIS11b delayed migration of the radiolabeled VEGF 3 0 -UTR probe (lane 3), and addition of a polyclonal anti-TIS11b antibody (anti N-ter) resulted in a supershift of the probe-protein complex (lane 6). The complex was specific since it was disrupted in the presence of an excess of unlabeled probe (lanes 4 & 5) and was not observed in the presence of a control bacterial extract (lane 1). These results suggested that the regulatory effects observed in Figure 1a -c resulted from the formation of a molecular complex between TIS11b and the 3 0 UTR of VEGF mRNA.
Identification of the TIS11b-binding site within VEGF mRNA 3 0 -UTR Our next goal was to identify the TIS11b-binding sequence within the VEGF 3 0 UTR. In silico analysis of the 2201 bp-long rat VEGF 3 0 -UTR revealed the presence of two nonameric UUAUUUA(A/U)(A/U) and seven pentameric AUUUA motifs (Figure 2a ). We constructed various deletion mutants of the Luc-V3 0 expression plasmid (shown in Figure 2a ) and cotransfected them with a TIS11b expression plasmid into 3T3 fibroblasts. The inhibition of luciferase activity induced by TIS11b was determined under each condition (Figure 2b ). Deletion of a large fragment of the VEGF 3 0 UTR containing all ARE motifs (DARE) abrogated the inhibitory effect of TIS11b on reporter gene activity by 80%. Deletion of sequences 3 0 or 5 0 to the NsiI site at position 1255 (Nsi-5 0 and Nsi-3 0 , respectively) clearly indicated that the TIS11b-binding element was located in Nsi-5 0 , that is, between nt 0-1255. Further truncation of this sequence allowed us to localize a 75 bp sequence (nt 1161-1235) that responded to TIS11b similarly although slightly less than the full-length construct. This sequence is subsequently referred to as TBE (TIS11b-binding element). TBE contains one nonameric (N) and one pentameric (P) consensus motifs that are both conserved in the human VEGF sequence. We prepared single and double mutants of these motifs. Each mutation (N, P and N/P) prevented TIS11b inhibitory effect similarly to the DARE construct. This strongly suggested that each of the two AREs present within this 75 bp-long sequence is involved in TIS11b-binding and regulatory activity.
We next examined the association between TIS11b and the 2201 bp-long VEGF 3 0 -UTR by UV crosslinking of the radiolabeled RNA probe to the recombinant protein. As shown in Figure 2c , after RNAse digestion, a covalent RNP complex with an apparent molecular size of 38 kDa could be detected by PAGE-SDS. An excess of unlabeled 75 bp TBE sequence (Figure 2c ) totally inhibited the interaction. This confirmed that TBE is likely to be the primary TIS11b-binding domain within the VEGF 3 0 UTR. We next attempted to crosslink the radiolabeled 75 bp-long TBE RNA and the recombinant TIS11b protein. The results shown in Figure 2d clearly demonstrate the formation of a molecular complex between TBE and TIS11b that is dissociated by excess unlabeled wild-type probe but resists to an excess of any of the mutant TBE RNA probes (N, P and N/P). The failure of the double mutant TBE probe to associate with TIS11b was further demonstrated by a direct UV crosslinking experiment ( Figure 2e ). Taken together, the results of the UV crosslinking experiments confirmed that each of the two ARE motifs present in the TBE sequence is essential for TIS11b binding.
In vivo interaction between TIS11b and VEGF 3 0 UTR
After characterizing the interaction between TIS11b and VEGF 3 0 UTR in vitro, our next goal was to demonstrate that this interaction could also occur in live cells. For this, we transfected NIH 3T3 cells with pCMV-TIS11b and pLuc-V3 0 plasmids and subsequently subjected them to in vivo crosslinking. TIS11b-containing RNP complexes were then immunoprecipitated from cell lysates using a specific anti-TIS11b antibody (anti Cter) and the immunoprecipitates were subjected to RT-PCR amplification of the firefly luciferase mRNA. As shown in Figure 3 , luciferase mRNA was specifically detected in anti-TIS11b immunoprecipitates, whereas it was only detectable in the supernatants of the control immunoprecipitations. These results demonstrate that the TIS11b-VEGF 3 0 UTR interaction occurs not only in reconstituted in vitro systems but also in living cells.
Effect of TIS11b 'knockdown' on VEGF mRNA expression
We have previously shown that ACTH treatment of primary adrenocortical cells results in a rapid and 0 -UTR. Control (CTL) and TIS11b-expressing (TIS11b) bacterial extracts were prepared as described in Materials and methods. They were incubated with radiolabeled full-length VEGF 3 0 -UTR RNA probe (FL*) in the absence or presence of a 2.5-fold (lane 4) or fivefold (lanes 2 and 5) excess of unlabeled competitor probe (Comp.). Then, 0.5 mg of anti-TIS11b IgGs was added to the incubation mixture in lane 6. The ribonucleoprotein complexes were then analysed by EMSA as described in Materials and methods. The bracket encompasses the retarded probe and the arrow points to the suspershifted (SS) antibody-TIS11b-probe complex Destabilization of VEGF mRNA by TIS11b D Ciais et al transient increase in VEGF mRNA levels and a delayed but sustained induction of TIS11b mRNA (Chinn et al., 2002) . To determine the contribution of TIS11b in the regulation of VEGF mRNA expression by ACTH, we used the RNA interference methodology. Following transfection with siRNA duplexes targeting four regions (Ts1-Ts4) in TIS11b gene, bovine adrenocortical cells were incubated in the presence or in the absence of ACTH for the indicated periods of time as described in 'Materials and methods' section. As shown in Figure 4a , 0 -UTR of VEGF mRNA. Deletion constructs were generated from the full-length 3 0 -UTR of VEGF mRNA using the restriction sites indicated in the upper part of the figure. The TBE fragment (nt 1161-1235) was mutated to invalidate either one or both AREs. Flags with white circles represent the nonameric ARE motif UUAUUUA(A/U)(A/U) and those with black circles represent the pentameric motif AUUUA. Flags with gray squares represent mutated motifs. (b) Mapping of the sequence in VEGF mRNA 3 0 -UTR required for TIS11b inhibition of reporter gene activity. 3T3 cells were cotransfected with 10 ng of a TIS11b (or b-galactosidase as a control) expression plasmid, 5 ng of a plasmid encoding renilla luciferase and 500 ng of either one of the plasmids encoding firefly luciferase cloned upstream of the constructs described in (a). The TIS11b-induced inhibition of luciferase activity observed with each construct was compared to that obtained with the full-length (FL) 3 0 -UTR. Results are expressed as the mean7s.e. of duplicate determinations. Values with identical superscript letters are not statistically different (P>0.05). This is a representative experiment of three independent experiments that produced similar results. (c-e) Mapping of the TIS11b-binding sequence in VEGF mRNA 3 0 -UTR. Radiolabeled polyadenylated RNA probes encoding some of the constructs shown in (a) were UV crosslinked to control (CTL) or TIS11b-expressing (TIS11b) bacterial extracts. Either full-length (FL) 3 0 -UTR (c), intact TBE (TBE) (d, e) or doublemutated TBE (TBE mutN/P) (e) was used as probes. A fivefold excess of unlabeled competitor RNA (Comp.) was added to some assay conditions, as indicated. After RNAse T1 digestion of the unprotected probes, the complexes were analysed by 10% PAGE-SDS. The position and size (in kDa) of MW standards are indicated on the left of panel c. Arrowheads point to the position of the 38 kDa TIS11b-probe complexes. The upper bands correspond to complexes between probes and bacterial proteins unrelated to TIS11b (Figure 4b and d) . In ACTH-stimulated cells, siRNA treatment enhanced the hormone-induced expression of VEGF by 60-150%. Altogether, these results indicate that TIS11b is an important negative regulator of VEGF mRNA levels under basal condition and to a larger extent under ACTH treatment.
Discussion
Post-transcriptional regulation of VEGF mRNA is a key process in the control of VEGF expression. VEGF mRNA has a short half-life and its stabilization has been shown to strongly contribute to the induction of VEGF expression that is observed under hypoxic conditions (Levy et al., 1996) . Several domains of VEGF mRNA 3 0 UTR are involved in hypoxic stabilization of Figure 3 In vivo interaction between TIS11b and VEGF 3 0 UTR. 3T3 cells were cotransfected with a TIS11b expression plasmid and pLuc-V3 0 . At 24 h after transfection, RNP complexes were crosslinked in living cells, as described in Materials and methods. The complexes containing TIS11b were then immunoprecipitated with anti-TIS11b IgGs and protein A-agarose. Controls included the addition of nonimmune IgGs or no IgG. The supernatants (SUP) and immunoprecipitates (IP) were collected separately and the luciferase mRNA was amplified by RT-PCR and analysed, as described in Materials and methods. The Input lane shows the results of a parallel reaction performed with total RNP complexes that were not subjected to immunoprecipitation Figure 4 siRNA-induced TIS11b gene repression leads to upregulation of VEGF expression. Bovine adrenocortical cells in primary culture were transfected with or without a 10 nM solution of four 21-mer siRNA duplexes as described in the 'Materials and methods' section. After 48 h, cells were either lysed to evaluate TIS11b knockdown or incubated with fresh medium in the absence or in the presence of 10 nM ACTH for the indicated period of time. (a) Effect of siRNA treatment on TIS11b expression. The content of TIS11b protein in total cell lysates from nontransfected (Cont) or siRNA-treated cells was analysed by immunoblotting as described in Materials and methods section. Scrambled siRNA (Scr) served as nonspecific control siRNAs. siRNA duplexes Ts1, Ts2, Ts3, Ts4 were tested either separately or altogether. The combination of the four siRNA was more efficient in knocking down TIS11b gene expression. Immunodetection of a-Tubulin was used to check for protein loading in each lane. (b-d) Effect of TIS11b knockdown on VEGF expression. At each time point of stimulation by ACTH, total RNA was isolated and RT-PCR analysis was performed to determine TIS11b, VEGF or HPRT mRNA expression levels (b). Amplification products were quantitated using a Fluorimager and normalized to HPRT (c, d) Destabilization of VEGF mRNA by TIS11b D Ciais et al VEGF mRNA through the recruitment of several specific AREs-binding proteins. These include HuR and hRNP-L (Levy et al., 1998; Shih and Claffey, 1999) . The existence of antagonistic proteins, favoring VEGF mRNA degradation, has been postulated but never demonstrated. To our knowledge, our present work is the first to report the identification of such an AREbinding protein that negatively regulates the stability of VEGF mRNA.
Three major conclusions can be drawn from the results of the present work: (i) a functional interaction between TIS11b and VEGF mRNA 3 0 UTR results in decreased VEGF mRNA stability and mRNA levels; (ii) the site of TIS11b interaction with the VEGF mRNA 3 0 UTR is restricted to a 75 bp-long sequence that contains one nonameric and one pentameric AU-rich motifs; (iii) TIS11b participates to the physiological regulation of basal as well as ACTH-induced VEGF expression.
Interestingly, the TBE identified in the present study is located very close to a recently described HuRbinding element (Goldberg-Cohen et al., 2002) . Proximity of HuR-and TIS11b-binding elements in VEGF 3 0 UTR suggests that stabilizing and destabilizing AREbinding proteins may compete for binding to similar regions of the 3 0 UTR as it has been recently observed for several cytokine mRNAs (Raghavan et al., 2001) . Interestingly, this TBE sequence has previously been shown to be involved in the stabilization of VEGF mRNA after JNK and p38/HOG activation (Pages et al., 2000) . In this study, the stimulation of stress-activated protein kinases induced the formation of a RNP complex that bound to a region containing the TBE and triggered stabilization of VEGF mRNA. Furthermore, it was reported that phosphorylation of TIS11 (TTP) by p38 kinase could reduce its binding affinity for ARE motifs (Carballo et al., 2001) . One could then extrapolate that p38 activation might disrupt the TIS11b-TBE complex and allow recruitment of a stabilizing ARE-binding protein which remains to be identified.
The second important finding of this work relates to the modulation of VEGF expression by TIS11b in vivo. We bring evidence that TIS11b and VEGF 3 0 UTR directly interact in living cells, and that TIS11b participates in the physiological regulation of VEGF expression by accelerating the turnover of VEGF mRNA. Using RNA interference in primary adrenocortical cells, we confirmed our previous hypothesis postulating that the mRNA destabilizing activity of TIS11b is involved in the decay phase of ACTH-elicited VEGF mRNA levels (Chinn et al., 2002) . Reducing endogenous TIS11b expression by 75% caused a small increase in basal and a marked increase in ACTHinduced VEGF mRNA levels. This indicates that TIS11b plays an essential role as a limiting factor for VEGF expression. One could speculate that a complete knockdown of TIS11b gene may result in a sustained hormone-induced expression of VEGF mRNA. It is also possible that TIS11b participates in the control of the stability of many other ACTH target genes. For example, the gene encoding StAR (Steroidogenesis Acute Regulatory protein), a mitochondrial protein essential for cholesterol transfer to the inner mitochondrial membrane, is a likely candidate as its expression is rapidly and transiently induced by ACTH in adrenocortical cells (Brand et al., 1998) and since several AREs are present in its mRNA 3 0 -UTR (Ariyoshi et al., 1998) . Alterations of mRNA stabilization have been reported to occur during tumour growth (Ross et al., 1991) . Very recently, it has been reported that TTP acts as a potent tumour suppressor when overexpressed in a v-H-ras-dependent mast cell tumour model (Stoecklin et al., 2003) . Our results would suggest that this effect could result from decreased VEGF mRNA levels and decreased angiogenesis. Unfortunately, tumor vascularization was not documented in this study.
In conclusion, our results suggest that TIS11b might represent a novel antiangiogenic and antitumoral agent acting through its destabilizing activity on VEGF mRNA. Future studies from our laboratory will address this question.
Materials and methods

Plasmid constructs
Plasmids containing the firefly luciferase cDNA cloned upstream of the rat VEGF 3 0 -UTR and downstream of the thymidine kinase promoter (pLuc-V3 0 and truncations) were derived from the pSp64 plasmids described in Levy et al., 1996 . The sequences of wild-type and mutant TBE are shown in Table 1 . Human TIS11b cDNA was obtained by PCR from H295R cells and cloned into pTarget (Promega, Madison, WI, USA) to generate pCMV-TIS11b and into pGEX4-T to generate pGEX-TIS11b. The pCMV-TIS11 and pCMVTIS11d plasmids were generated by cloning mouse TIS11 and TIS11d cDNAs (kindly provided by Dr KD Brown, Babraham Institute, Cambridge, UK) into pTarget. PRK7-bgal is a control plasmid in which b-galactosidase expression is driven by the CMV promoter. pRL-TK encoding renilla luciferase was obtained from Promega.
Quantitative RT-PCR
Quantitative RT-PCR was performed on a Light Cycler apparatus using SYBR green PCR core reagents (Roche Diagnostics, Mannheim, Germany). The following primers and conditions were used for luciferase: CGCCAAAAGCAC TCTGATTGA and CCTTGTCGTATCCCTGGAAGATG (951C for 15 s, 551C for 5 s, 721C for 10 s; 45 cycles in 3 mM MgCl 2 ) and for GAPDH: AACGACCCCTTCATTGAC and TTCACGACATACTCAGCA (951C for 15 s, 571C for 5 s, 721C for 10 s; for 45 cycles in 4 mM MgCl 2 ).
DNA transfection and dual luciferase activity assay NIH-3T3 fibroblasts were grown in DMEM supplemented with 10% fetal calf serum and transfected using lipofectamine (Invitrogen, Cergy-Pontoise, France). Various amounts (1-50 ng) of either pCMV-TIS11b, pCMV-TIS11, pCMVTIS11d or PRK7-bgal were cotransfected with 500 ng pLuc-V3 0 , 5 ng of pRL-TK and pUC19 up to a total of 1 mg plasmid DNA into 3 Â 10 5 cells. Renilla and firefly luciferase activities were measured sequentially 48 h after transfection with the NIH-3T3 cells using lipofectamine.
Production of anti-TIS11b antibodies
Rabbit polyclonal antibodies to TIS11b were produced by CovalAb (Lyon, France) using two synthetic peptides from the NH2-and COOH-termini as immunogens. The anti-C ter and anti-N ter IgGs were then purified from the antiserum by affinity chromatography.
Bacterial expression of TIS11b
Overnight cultures of E. coli transformed with pGEX-TIS11b or pGEX4-T (control) were diluted with LB and grown at 301C to limit the formation of inclusion bodies. IPTG (0.5 mM) was added for 4 h to induce protein synthesis. Western blotting of the bacterial extract unexpectedly revealed the presence of a small proportion of GST-TIS11b fusion protein and a larger amount of untagged TIS11b presenting an expected MW of 38 kDa. The fusion protein was eliminated from the extracts by adsorption on glutathione-agarose beads.
EMSA and UV crosslinking assay 32 P-labeled and unlabeled riboprobes were synthesized in vitro using the riboprobe SP6 system kit (Promega). Integrity of RNA transcripts was determined using a lab-on-chip analyser (Bioanalyzer 2100, Agilent Technologies, Palo Alto, CA, USA). In all, 5 Â 10 5 c.p.m. of RNA transcripts were incubated for 20 min at room temperature with 10 mg of bacterial extracts in 10 mM HEPES pH 7.6, 3 mM MgCl 2 , 40 mM KCl, 5% glycerol, 0.5% NP40 and 2 mM DTT, in the presence or absence of specific competitors. Yeast tRNA (50 ng/ml) and heparin (2 mg/ml) were then added for 10 min and 0.5 mg of antiTIS11b Nter antibody was eventually added for another 10 min. Protein-RNA complexes were separated by electrophoresis on 4% polyacrylamide gels and visualized with a b-imager. For UV crosslinking studies, mixtures were prepared as for EMSA and exposed to UV light for 30 min at 41C. Then, 100 U of RNase T1 (Invitrogen) was added for 20 min and RNA-protein complexes were analysed by 10% PAGE-SDS.
RNP complex immunoprecipitation and analysis by RT-PCR
RNP complexes were immunoprecipitated after reversible crosslinking between RNA and proteins as previously described (Niranjanakumari et al., 2002) . Briefly, cell suspensions were incubated in 1% formaldehyde for 10 min at room temperature. The reaction was stopped by 0.25 M glycine and cells were lysed in RIPA buffer containing protease inhibitors. Protein A-agarose preadsorbed cell lysates were immunoprecipitated using protein A-agarose beads preincubated with 3 mg of anti-TIS11b antibody (anti-Cter), 3 mg of nonimmune IgG, or no protein. After crosslinking reversion at 701C for 45 min, RNA was isolated from supernatants and immunoprecipitates, treated with DNAse I (Invitrogen), and reverse transcribed with Superscript II (Invitrogen). A PCR amplification of the luciferase transcripts was then carried out using Taq polymerase (QBiogen, Illkirch, France) and the same primers used in quantitative PCR, under the following conditions: 941C for 1 min, 551C for 1 min and 721C for 1 min for 40 cycles. The PCR products were analysed by 2% agarose gel electrophoresis.
RNA interference
Expression of TIS11b was inhibited by transfection of siRNAs (Elbashir et al., 2001) . Briefly, primary cultures of bovine adrenocortical fasciculata cells were prepared by enzymatic digestion and cultured at 371C in Ham's F12 medium supplemented with 10% horse serum, 2.5% FCS and antibiotics as previously reported (Negoescu et al., 1994) . At 1 day after plating, adrenocortical cells were transfected with or without 10 nM of siRNA duplexes, using siPORT lipid reagent (Ambion, Austin, TX, USA). siRNA duplexes (21-nucleotide) were designed based on four 19 bp TIS11b cDNA regions (positions 128-147, 462-481, 848-867 and 1086-1105) , and generated using Silencer siRNA construction kit from Ambion. A Blast search on the NCBI database ensured specific targeting to TIS11b mRNA. Tis11b siRNA oligonucleotide templates were the following:
(1) antisense 3
0 . Scrambled siRNA duplexes of these targeting sequences served as nonspecific control siRNAs. Typically, cells were analysed for the loss of TIS11b mRNA and protein expression 48 h after transfection using either RT-PCR or immunoblotting. At this time point, culture medium was changed and cells were treated for the indicated periods of time with or without 10 nM ACTH. For RT-PCR analysis of TIS11b, VEGF or HPRT gene expression in siRNA-transfected cells, 2 mg of total RNA was reverse transcribed with Superscript II (Life Technologies) and PCR amplified using Taq polymerase (QBiogen, Illkirch, France) using the same primers and amplification conditions as described by Chinn et al. (2002) . Amplification products were analysed by 2% agarose gel electrophoresis and visualized under UV light.
SDS-PAGE analysis and immunoblotting
SDS-polyacrylamide (0.1%; 10%) gel electrophoresis was performed according to Laemmli (1970) . In total, 3 Â 10 6 primary adrenocortical cells, plated in 6-cm Petri dishes, were lysed in RIPA buffer (in the presence of protease inhibitors) following 48 h treatment by TIS11b siRNA. The lysate was cleared by centrifugation for 10 min at 10 000 g at 4 C. Aliquots of 10 mg were resolved by SDS-PAGE and transferred onto a polyvinylidene fluoride (PVDF) membrane which was incubated in blocking buffer (PBS, 0.1% Tween 20, 5% nonfat dry milk) for 1 h, then exposed to 0.1 mg/ml of rabbit polyclonal anti-TIS11b antibody at room temperature for 2 h. The membrane was thoroughly washed with PBS/Tween buffer (3 Â 10 min), and then incubated for 1 h with horseradish peroxidase-labeled goat anti-rabbit IgG. The PVDF sheet was then washed for 4 Â 10 min and the antigen-antibody complex was revealed by Enhanced Chemiluminescence using the Western blotting detection kit from Amersham Biosciences (Orsay, France). The same membrane was stripped and reprobed with a monoclonal antibody for a-tubulin (a generous gift from Dr D Job, CEA-Grenoble) to check for loading of protein in each lane.
Statistical analysis
Results are expressed as the mean7s.d. Statistical comparisons were made using one-way ANOVA test (StatView, Abacus Concepts Inc., Berkeley, CA, USA). A value of Po0.05 was considered as statistically significant.
Abbreviations VEGF, vascular endothelial growth factor; TIS11, TPA-induced sequence 11; TTP, tristetraprolin; 3 0 -UTR, 3 0 -untranslated region; ARE, AU-rich element; DRB, 5,6-dichloro-1-d-Dribofuranosyl benzimidazole; TNFa, tumour necrosis factor a; GM-CSF, granulocyte macrophage colony-stimulating factor; PVDF, polyvinylidene fluoride.
